Skip to content
AlternativeMed
Carrageenan close-up
Carrageenan powder beside dried red seaweed.

Seaweed & Algae · Seaweed extract

Carrageenan

Extract of red seaweeds (Chondrus, Eucheuma and related) · also called Carrageenan gum, E407, E407a (processed Eucheuma seaweed)

Carrageenan is a thickener and gelling agent taken from red seaweeds. It holds together dairy and plant drinks, desserts and processed meats. It is not a nutrient food. Regulators accept it at current use, but the question is not closed: the EU keeps its limit as temporary, and the human studies are tiny. People with ulcerative colitis, and parents choosing infant formula, should ask a doctor.

General information, not medical advice. Last substantive update · Not medically reviewed. A named clinician has not signed off on this page. How this page is made

Get your Carrageenan today. Order now from Amazon and have it delivered to your door.Shop Carrageenan on AmazonSupport our free guides: as an Amazon Associate we earn from qualifying purchases.

About Carrageenan

Carrageenan is a thickener from red seaweed, used in many processed foods. It is accepted by regulators at current use, but the EU limit is temporary and the human studies are very small. The strongest worries come from animal work on a broken-down form that is not allowed in food.

What it is

Carrageenan is a sulfated sugar chain taken from red seaweeds. The US regulation describes it as the refined extract of red seaweeds in the families Gigartinaceae and Solieriaceae, with 20 to 40 percent sulfate. It is used in the amount needed as an emulsifier, stabilizer or thickener.

In Europe it is E 407, and processed Eucheuma seaweed, a less refined product, is E 407a. EFSA found it is not absorbed intact. It is not a nutrient food: no nutrition table was read for this page, and the figures that exist are regulators' limits, not advice on how much to eat.

10 9

Two things share the name

Poligeenan, also called degraded carrageenan, is a much smaller molecule made on purpose with strong acid and heat. EFSA says it has never been authorised as a food additive and is not used in food. Much of the animal work on gut ulcers and tumours used this form, and for years it was labelled carrageenan.

The two sides disagree on whether food-grade carrageenan can turn into the harmful form in the gut. A 2001 review by Tobacman argued that it can and said use should be reconsidered. A 2019 review and a 2017 addendum by industry-linked authors say it cannot and that many harm claims confuse the two. Neither side's papers prove the question in people.

6 4 8 9

What the research shows

Regulators: EFSA (2018) found no concern for cancer or genetic damage, and rats showed no harm at the highest doses tested. It still kept the group limit of 75 mg per kg body weight per day as temporary because of gaps in the chemistry, intake data and biology. JECFA lists the limit as not specified.

People: three small studies exist. In 12 people with ulcerative colitis, 3 on carrageenan capsules relapsed and none on placebo did. In 20 healthy men, 2 weeks of capsules did not change insulin sensitivity overall, but overweight men had lower sensitivity and higher CRP and IL-6. A survey of 922 adults using protein drinks saw no overall link with CRP. None of these tested ordinary food.

9 11 1 7 3

Additive versus whole seaweed and capsules

Carrageenan is a refined extract, not whole sea moss or Irish moss. The trials used capsules and the survey used protein drinks. No study compared the additive with the whole seaweed, so findings should not be carried across. Sea moss has its own page.

10 7 1

At a glance

Traditional uses history, not proof

  • The refined extract is a modern food additive
  • Red seaweeds such as Irish moss are eaten as food; no traditional medicine use was verified

Studied for research

  • Safety at current food use, accepted by regulators with open questions (EFSA, JECFA, FDA)
  • Ulcerative colitis relapse, very low certainty (12 people finished)
  • Insulin sensitivity, very low certainty (20 healthy men, 2 weeks)
  • Inflammation marker CRP, very low certainty (survey)
  • Gut tumours and ulcers, animal and lab evidence only
  • Use as a food thickener (technical use, not a health benefit)

Main compounds

  • Kappa, iota and lambda carrageenan (sulfated polysaccharides)
  • Low-weight carrageenan fraction
  • Poligeenan (degraded carrageenan, not a food additive)

Common forms

  • Refined carrageenan (E 407)
  • Processed Eucheuma seaweed (E 407a)
  • Capsules used in two small trials, not a food form
  • Whole sea moss and Irish moss are different products and are not covered

Research links: EFSA 2018 re-evaluation of carrageenan (E 407) · 2017 trial: carrageenan and ulcerative colitis relapse · 2024 trial: carrageenan and insulin sensitivity · Research Library · Genes & Biomarkers Library

What it is and its history

Accepted scientific name
Carrageenan (E 407): refined extract of red seaweeds
Naming authority
Not a single species. The US regulation names Chondrus crispus, Chondrus ocellatus, Eucheuma cottonii, Eucheuma spinosum and several Gigartina species (families Gigartinaceae and Solieriaceae).
Common names
Carrageenan (English); Carrageenan gum (English); E407 (English); E407a (processed Eucheuma seaweed) (English); Carragenina (Spanish)
Family or group
Gigartinaceae and Solieriaceae, the red seaweed families named in the US regulation. Carrageenan itself is a refined seaweed extract, not a plant part.
Classification
Not stated by the sources read > Red algae > Rodophyceae (as written in the regulation) > Not stated > Gigartinaceae and Solieriaceae (per the regulation) > Chondrus, Eucheuma, Gigartina > Several; see accepted_name
Native range
Not verified from a source read.
Habitat
Not verified from a source read.
Cultivation
Not verified from a source read.
Harvest and processing
Refined carrageenan is prepared by aqueous extraction from the named red seaweeds (US regulation). Processed Eucheuma seaweed (E 407a) is a less refined seaweed product with more cellulose, and is sometimes bleached (EFSA).
Look-alikes and adulterants
Name: Poligeenan (degraded carrageenan); Note: A far smaller molecule made with acid and heat; not a food additive.; Name: Agar, alginate and whole sea moss; Note: Other seaweed gelling agents and the whole seaweed; they have their own pages and are different products.
Sustainability and conservation
Not assessed.

Photographs

Carrageenan close-up
Carrageenan powder beside dried red seaweed.

Traditional use and history history, not clinical proof

Tradition or eraDocumented useSource
Regulatory history (EFSA's account)JECFA set an acceptable daily intake of 0 to 75 mg per kg body weight in 1974. In 1984 it changed to 'not specified', and in 2002 it set a group 'not specified' for carrageenan plus processed Eucheuma seaweed. The EU scientific committee kept 0 to 75 mg per kg in 1978 and 1996. In 1983 IARC rated carrageenan group 3.EFSA 2018 (full text read); verified
Traditional seaweed useIrish moss (Chondrus crispus) is a traditional food seaweed, but no source read documents its history or any traditional medicine use. Not verified.NOT verified (no source read)

Traditional use shows how it was used. It does not show that it works or is safe today.

What is inside, and how it may work

What it contains and how those compounds act in cells and animals. Laboratory and animal mechanisms are not proven effects in people.

Main compounds

CompoundFamilyWhere it is concentratedActivity studiedLevel of evidence
Carrageenan polysaccharides (kappa, iota, lambda)sulfated polysaccharideRed seaweed thallus (extracted)
20 to 40 percent sulfate on a dry-weight basis (US regulation); EU: kappa, iota and lambda forms by number of sulfate groups
Gives thickening and gelling in foods. It is not absorbed intact (EFSA). 10 9Regulation
Low-weight carrageenan fraction (below 50 kDa)sulfated polysaccharide fragments
EFSA refers to an existing 5% limit on this fraction in the EU specification; not checked against the current regulation
Associated with potential gut inflammation because it resembles poligeenan (EFSA). 9Regulatory
Poligeenandegraded carrageenan
Average molecular weight 10 to 20 kDa (EFSA)
Causes gut inflammation and tumours in animals; not a food additive. 9 6Animal research

Mechanisms, receptors and pathways

Target or pathwayGene or receptorWhat was foundLevel
Inflammation signals in gut and immune cellsToll-like receptor and BCL10, NF-kB, IL-8 (cell studies, as reported by EFSA)In cell studies, carrageenan switched on NF-kB and IL-8 through Toll-like receptor and BCL10. EFSA noted that many of these tests did not describe which carrageenan was used. In the 2024 trial, carrageenan raised immune-cell activation in cells from the participants. These are lab findings. 9 7Lab
Breakdown of food-grade into degraded carrageenanNot applicableTobacman suggests food-grade carrageenan may be broken down by stomach acid or gut bacteria; McKim and colleagues (industry-linked) say it cannot become poligeenan in the body. The question is open in people. 6 4Disputed

Absorption, metabolism and elimination

Absorption
Not absorbed intact (EFSA); not degraded or absorbed in the gut in the species studied (Cohen and Ito 2002).
Metabolism
Not found.
Elimination
Not found in the sources read.
Bioavailability
Not established in people.

9 2

Isolated compounds versus whole extracts

Carrageenan is a refined extract, not whole seaweed. The animal work on gut damage mostly used the degraded form. The trials used capsules, not food. No study compared the additive with whole sea moss or Irish moss.

Nutritional composition

No nutrition table was read for this page. Carrageenan is an additive used in small amounts, not a nutrient source, and the earlier summary reports no USDA FoodData Central entry. For the whole seaweed, see the sea moss page. Regulators' only quantity is a limit: the EU group acceptable daily intake of 75 mg per kg of body weight per day (temporary), against JECFA's 'not specified'. That is a regulator's safety limit, not advice on how much to eat.

5benefits and uses looked at
11studies and sources checked
High certaintybest evidence rating found
4lab markers tracked in trials

1 high certainty3 very low certainty1 not enough evidence

What was looked at

The 5 benefits and uses checked for Carrageenan, each with how strong the evidence is. Tap one to open it.

Lab markers tracked in the studies

Interleukin-6 and fecal calprotectin (gut inflammation markers)Insulin sensitivityC-reactive protein (CRP)Gut permeability (leaky gut markers)

What is Carrageenan good for?

What has been studied and how strong the human evidence is. Most of these are safety questions, not benefits. The evidence is small and mostly very low.

Benefits, one by one

Each card is a research question, not a promise. Tap a goal to filter. Open a card to see the studies, doses and limits.

Gut inflammation: ulcerative colitis relapse (a safety question)

Very low certainty

One very small trial asked whether carrageenan capsules bring on earlier relapse in people with ulcerative colitis in remission. Three of those given carrageenan relapsed and none given placebo did, but only 12 people finished. This is a possible harm, not a benefit.

2 studiesCapsules with less carrageenan than the average daily intake from die…

Studies, doses and limits

What the trials found

One randomised, double-blind trial: 12 people finished. 3 given carrageenan capsules relapsed; none given placebo did (p = 0.046). IL-6 rose in the carrageenan group (p = 0.02); fecal calprotectin rose with p = 0.06.

Results

A signal of possible harm in a tiny trial. It cannot settle the question, and EFSA says it needs further investigation.

Effect sizes as reported

3 relapses of the carrageenan group versus 0 of the placebo group among 12 completers; log-rank p = 0.046.

Why this rating

Very low: 12 completers, one trial, capsules rather than food, and authors who started with a concern about carrageenan.

Form and dose studied

Capsules with less carrageenan than the average daily intake from diet (amount not given in the abstract). Not a food form.

Who was studied

Adults with ulcerative colitis in remission.

Limits

Tiny sample. Capsules, not foods. Not repeated in the sources we read.

Why researchers looked

Carrageenan is in many processed foods, and lab and animal work (mostly with the degraded form) linked it to gut inflammation, so researchers tested it in people with ulcerative colitis.

Traditional use

Carrageenan is made from red seaweeds, which have long been eaten in Ireland and other places. The extract is a modern food additive and has no traditional medicine use we could source.

Proposed mechanism In vitro and regulatory summary

In cell studies carrageenan switched on inflammation signals. EFSA says many of those tests did not describe which kind of carrageenan was used, and that results suggesting it might worsen inflammatory bowel disease in people need clarification.

A proposed mechanism does not show that the effect happens in people.

If you have ulcerative colitis or Crohn's disease, ask your gut doctor; see the Safety tab.

1 9

Gut ulcers and tumours in animals (lab and animal evidence only)

Not enough evidence

Animal studies of the broken-down form (poligeenan) clearly caused gut damage. Whether the food additive does the same is disputed. Regulators judge the food additive acceptable; critics disagree. No human result shows either.

5 studiesMostly degraded carrageenan (poligeenan) or poorly described samples;…

Studies, doses and limits

What the trials found

No human trial of tumours or gut ulcers was found.

Results

Animal and lab only. A critical review (Tobacman 2001) says both forms were linked to ulcers and tumours in animals. A 2002 review (Cohen and Ito) found no credible evidence of cancer or colon tumour promotion for food-grade carrageenan and noted that many studies used doses far above human intake.

Effect sizes as reported

No numbers in the abstracts. EFSA: rats showed no effects at the highest doses tested (3,400 to 3,900 mg per kg body weight per day in a subchronic study; up to 7,500 in chronic studies); monkeys given degraded carrageenan had colon lesions.

Why this rating

Insufficient for people: animal and lab work only, with sides that disagree and industry links on one side.

Form and dose studied

Mostly degraded carrageenan (poligeenan) or poorly described samples; this is not the food additive.

Who was studied

Rats, guinea pigs, pigs, monkeys.

Limits

Animal doses are far above human intake. Many studies did not say which form was tested. Two of the papers cited are linked to a carrageenan maker, and one is by a critic who has argued against carrageenan.

Why researchers looked

Early animal work used a degraded form to cause gut ulcers on purpose, which raised the question of the food additive.

Proposed mechanism Animal research

Tobacman (2001) suggested the damage could come from small-molecule contamination, breakdown in stomach acid, or gut bacteria. Industry-linked reviewers (FMC-linked) say food-grade carrageenan cannot turn into the degraded form in the body. EFSA says the colon findings relate mainly to the degraded form.

A proposed mechanism does not show that the effect happens in people.

See the Safety tab for what EFSA, JECFA and FDA concluded.

6 2 4 8 9

Insulin sensitivity and blood sugar control (a safety question)

Very low certainty

A small two-week crossover trial in 20 healthy young men found no overall change in insulin sensitivity from carrageenan capsules. In the overweight men, insulin sensitivity was lower and inflammation markers higher. It is a possible harm signal that needs repeating.

2 studiesCarrageenan capsules, 250 mg twice a day for 2 weeks, in a trial; not…

Studies, doses and limits

What the trials found

Randomised, double-blind, placebo-controlled crossover trial, 20 men, carrageenan 250 mg in the morning and evening for 2 weeks. Overall insulin sensitivity did not differ. In overweight participants insulin sensitivity was lower, CRP and IL-6 were higher and gut permeability was higher (interaction p = 0.01 to 0.04).

Results

No overall effect; a possible harm in overweight men in one small trial.

Effect sizes as reported

Overall: no significant difference. BMI-by-treatment interactions: p = 0.04 (OGTT-based index), p = 0.01 (fasting insulin resistance), p = 0.04 (liver insulin sensitivity index).

Why this rating

Very low: 20 healthy young men, 2 weeks, capsules, and the finding is a subgroup effect.

Form and dose studied

Carrageenan capsules, 250 mg twice a day for 2 weeks, in a trial; not a food form.

Who was studied

Healthy young men.

Limits

Small, short, men only, capsules, subgroup finding.

Why researchers looked

Animal studies suggested carrageenan could make the body less sensitive to insulin and raise gut inflammation.

Proposed mechanism Human trial interpretation

The authors propose pro-inflammatory effects in the gut and raised gut permeability. This is their interpretation of trial and cell results, not a tested mechanism.

A proposed mechanism does not show that the effect happens in people.

People with diabetes or prediabetes: ask your doctor; see the Safety tab.

7 9

Inflammation marker CRP (survey of protein-drink users)

Very low certainty

A US survey of 922 adults who use protein drinks found no clear link between carrageenan-containing drinks and the inflammation marker CRP. In people who said their health was poor, the numbers were higher, but this was a subgroup finding.

1 studiesCarrageenan in protein drinks, amount not measured.

Studies, doses and limits

What the trials found

Observational survey (NHANES) of 922 US adults using protein supplement beverages. Overall ratio of CRP 1.07 (95% CI 0.74 to 1.55) for carrageenan-containing liquid drinks against powder drinks; 0.98 (0.66 to 1.47) in the second analysis.

Results

No overall link; a possible link in people in poorer health that the authors call hypothesis-generating.

Effect sizes as reported

Primary ratio 1.07; secondary 0.98; in poorer health 1.91 (0.92 to 3.97) and 3.14 (1.43 to 6.91); interaction p = 0.04.

Why this rating

Very low: a survey that guessed exposure from the type of drink, with a subgroup signal.

Form and dose studied

Carrageenan in protein drinks, amount not measured.

Who was studied

US adults using protein drinks.

Limits

Cannot show cause. Exposure was guessed. One author's spouse works for PepsiCo.

Why researchers looked

Researchers wanted to know whether carrageenan in everyday products goes with higher inflammation in the real world.

Proposed mechanism Not applicable

Not tested in this survey.

A proposed mechanism does not show that the effect happens in people.

None specific.

3

Use in foods as a thickener, gelling agent and stabiliser (technical use, not a health benefit)

High certainty

Carrageenan is used to hold dairy and plant drinks, desserts and meats together. That is a food-making job, not a health effect.

2 studiesRefined carrageenan (E 407, US 21 CFR 172.620) and processed Eucheuma…

Studies, doses and limits

What the trials found

Not a health trial. FDA's regulation allows it as an emulsifier, stabilizer or thickener in the amount necessary.

Results

A technical use only. We make no health claim.

Why this rating

High that this is what it is used for and how regulators define it (regulation text read). No health benefit is claimed.

Form and dose studied

Refined carrageenan (E 407, US 21 CFR 172.620) and processed Eucheuma seaweed (E 407a).

Limits

Says nothing about health effects.

Why researchers looked

Regulators review it because it is eaten widely in processed foods.

Traditional use

Red seaweeds have been eaten for centuries; the refined extract is a modern industrial ingredient.

Proposed mechanism Regulation

Carrageenan is a sulfated polysaccharide of galactose and anhydrogalactose; FDA text gives 20 to 40 percent sulfate.

A proposed mechanism does not show that the effect happens in people.

See the Safety tab.

10 9

Connections to the rest of health

How Carrageenan connects to the rest of our health knowledge graph. Every link says what kind of connection it is. A safety link (for example to the liver) is a warning, not a benefit. A study that merely mentions a topic never creates a benefit link.

Explore every connection: goals, body systems, organs, symptoms, genes

A. Wellness goals

Connected toKind of connectionEvidence statusContextStudies
Gut Health Very low certainty Gut inflammation: ulcerative colitis relapse (a safety question): One very small trial asked whether carrageenan capsules bring on earlier relapse in people with ulcerative colitis in remission. Three of those given carrageenan relapsed and none given placebo did, but only 12 people finished. This is a possible harm, not a benefit. 1 9
Digestive Support Very low certainty Gut inflammation: ulcerative colitis relapse (a safety question): One very small trial asked whether carrageenan capsules bring on earlier relapse in people with ulcerative colitis in remission. Three of those given carrageenan relapsed and none given placebo did, but only 12 people finished. This is a possible harm, not a benefit. 1 9
Gut Health Not enough evidence Gut ulcers and tumours in animals (lab and animal evidence only): Animal studies of the broken-down form (poligeenan) clearly caused gut damage. Whether the food additive does the same is disputed. Regulators judge the food additive acceptable; critics disagree. No human result shows either. 6 2 4 8 9
Digestive Support Not enough evidence Gut ulcers and tumours in animals (lab and animal evidence only): Animal studies of the broken-down form (poligeenan) clearly caused gut damage. Whether the food additive does the same is disputed. Regulators judge the food additive acceptable; critics disagree. No human result shows either. 6 2 4 8 9
Blood Sugar Balance Very low certainty Insulin sensitivity and blood sugar control (a safety question): A small two-week crossover trial in 20 healthy young men found no overall change in insulin sensitivity from carrageenan capsules. In the overweight men, insulin sensitivity was lower and inflammation markers higher. It is a possible harm signal that needs repeating. 7 9
Inflammation Balance Very low certainty Inflammation marker CRP (survey of protein-drink users): A US survey of 922 adults who use protein drinks found no clear link between carrageenan-containing drinks and the inflammation marker CRP. In people who said their health was poor, the numbers were higher, but this was a subgroup finding. 3
Preventive Wellness High certainty Use in foods as a thickener, gelling agent and stabiliser (technical use, not a health benefit): Carrageenan is used to hold dairy and plant drinks, desserts and meats together. That is a food-making job, not a health effect. 10 9

B. Body systems

Connected toKind of connectionEvidence statusContextStudies
Digestive System Biological association Very low certainty Studied for: Gut inflammation: ulcerative colitis relapse (a safety question) Studied for: Gut ulcers and tumours in animals (lab and animal evidence only) 1 9 6 2 4 8 10
Endocrine System Biological association Very low certainty Studied for: Insulin sensitivity and blood sugar control (a safety question) 7 9
Immune System Biological association Very low certainty Studied for: Inflammation marker CRP (survey of protein-drink users) 3

E. Health conditions

Connected toKind of connectionEvidence statusContextStudies
Ulcerative colitis Preliminary, very small trial 3 of 12 finishers given carrageenan capsules relapsed; none on placebo did. 3 of 12 finishers on carrageenan capsules relapsed; none on placebo did.
Preparation or compound: Carrageenan capsules
1 9
Insulin resistance Preliminary, small trial No overall change in 20 healthy young men; lower insulin sensitivity in the overweight ones. No overall change in 20 healthy young men; lower sensitivity in overweight men.
Preparation or compound: Carrageenan capsules
7
Food allergy Adverse effect or risk One case report One anaphylaxis case during a barium enema; EFSA found no case reports from eating foods with carrageenan. One anaphylaxis case during a barium enema; none found from eating foods with carrageenan.
Preparation or compound: Carrageenan as an additive
5 9

I. Biomarkers

Connected toKind of connectionEvidence statusContextStudies
Interleukin-6 and fecal calprotectin (gut inflammation markers) Biological association Very low certainty Measured in trials: raised in the carrageenan group (IL-6); calprotectin trend. A lab change is not the same as a health benefit. 1
Insulin sensitivity Biological association Very low certainty Measured in trials: no overall change; lower in overweight participants. A lab change is not the same as a health benefit. 7
C-reactive protein (CRP) Biological association Very low certainty Measured in trials: mixed: higher in overweight men in a trial; no overall link in a survey. A lab change is not the same as a health benefit. 7 3
Gut permeability (leaky gut markers) Biological association Very low certainty Measured in trials: higher in the carrageenan period. A lab change is not the same as a health benefit. 7

K. Biological pathways

Connected toKind of connectionEvidence statusContextStudies
NF-kB inflammation signalling Preliminary mechanism Lab Switched on by carrageenan in cell studies (lab only). 9
Ulcerative colitis Preliminary mechanism Human One tiny trial saw earlier relapse; EFSA says it needs further investigation. 1 9
Insulin resistance Preliminary mechanism Human A small crossover trial saw a signal in overweight men. 7

L. Active compounds

Connected toKind of connectionEvidence statusContextStudies
Carrageenan polysaccharides (kappa, iota, lambda) Biological association Regulation Gives thickening and gelling in foods. It is not absorbed intact (EFSA).
Preparation or compound: Red seaweed thallus (extracted)
10 9
Low-weight carrageenan fraction (below 50 kDa) Biological association Regulatory Associated with potential gut inflammation because it resembles poligeenan (EFSA). 9
Poligeenan Biological association Animal Causes gut inflammation and tumours in animals; not a food additive. 9 6

Each connection is stored with the ingredient, the connected record, the kind of connection, the evidence status, the supporting studies, the preparation or compound involved, and a review date (last reviewed October 26, 2026).

The evidence

The research centre for Carrageenan. Every record here was checked against PubMed or the publisher's page; we never list a study we have not verified.

Evidence by outcome

Bars show how many studies we found for each outcome, not how well it works. People are added up across trials only (reviews are not added, to avoid double counting).

How we rate evidence

High certainty

Several well-run trials or reviews agree; further research is unlikely to change the picture much.

Moderate certainty

Good trials point the same way, but some doubt remains.

Low certainty

Small, short or inconsistent trials. The finding could change with better research.

Very low certainty

Very little or very weak human data. Treat as a possibility only.

Mixed findings

Trials or reviews disagree with each other.

Not enough evidence

Not enough human research to say either way.

Evidence against

Good research found no benefit, or found harm.

We take the reviewers' own risk-of-bias and GRADE statements where they exist, and otherwise judge from study size, design, consistency, directness and whether a product matches what is sold. Many publications do not make evidence high. Method note: We started from our existing carrageenan summary, read the EFSA 2018 opinion, the JECFA database page and the US regulation text, and re-read PubMed abstracts for the trials, reviews and a case report. Only abstracts were read for studies. Items we could not verify are flagged in the research gaps.

Study library: every study we checked 11
StudyDesignPeopleProduct, dose, lengthResult
Bhattacharyya 2017
A randomized trial of the effects of the no-carrageenan diet on ulcerative colitis disease activity.
Nutr Healthy Aging · PMID 28447072 · DOI
Randomised controlled trial
Adults with ulcerative colitis in remission; 12 completed the study questionnaires Carrageenan-containing capsules versus placebo capsules (carrageenan in the capsules was less than the average daily intake from diet)
Capsules Up to 1 year, or until relapse · vs Placebo capsules; all took part in a no-carrageenan diet
3 people given carrageenan capsules relapsed and none given placebo did (log-rank p = 0.046). Interleukin-6 rose in the carrageenan group (p = 0.02) and fecal calprotectin rose (p = 0.06, not significant) between start and end, not in the placebo group.
3 relapses with carrageenan versus 0 with placebo; IL-6 p = 0.02; fecal calprotectin p = 0.06 (Not given in the abstract)
Methods, limits and funding

Outcomes: Relapse (rise of 2 or more points on the SCCAI and stronger treatment), blood markers

Limitations: Only 12 people completed it, so one or two people can change the result. Capsules, not food. The senior author (Tobacman) is also the author of the 2001 review that argued against carrageenan, so the authors started with a view. Funding is not stated in the abstract.

Funding and conflicts: Funding is not stated in the abstract.

Read: abstract

Cohen 2002
A critical review of the toxicological effects of carrageenan and processed eucheuma seaweed on the gastrointestinal tract.
Crit Rev Toxicol · PMID 12389870 · DOI
Narrative review animal studies
animal
Animal toxicology studies of food-grade carrageenan and processed Eucheuma seaweed Food-grade carrageenan and processed Eucheuma seaweed
The authors found food-grade carrageenan is not broken down or absorbed in the gut of the species studied, found no credible evidence of cancer or tumour promotion in the colon of rodents, and noted that many studies used doses far above human intake. Poligeenan is not a food additive.
No numbers in the abstract (Not applicable)
Methods, limits and funding

Outcomes: Gut effects, absorption, cancer in animals

Limitations: A 2002 review of animal studies; it reflects the data then. Funding is not stated in the abstract.

Funding and conflicts: Funding is not stated in the abstract.

Read: abstract

Lam 2026
Evaluation of the Association Between Carrageenan and Systemic Inflammation: Results From the National Health and Nutrition Examination Survey.
Mol Nutr Food Res · PMID 42117307 · DOI
Cross sectional survey
922
922 US adults who used protein supplement beverages and had a CRP blood test (NHANES 1999-2010 and 2015-2023)
Carrageenan-containing liquid protein beverages (liquid products used as a stand-in for exposure) versus beverages made from powders
Protein supplement beverages · vs Powder-prepared beverage users; second analysis with versus without carrageenan (n = 622)
Overall, carrageenan-containing protein beverages were not significantly linked to CRP. In people who reported poorer health, ratios were higher (primary 1.91, 95% CI 0.92 to 3.97; secondary 3.14, 95% CI 1.43 to 6.91). The authors call this hypothesis-generating.
Primary ratio 1.07; secondary 0.98 (not significant); interaction with health status p = 0.04 (Primary 0.74 to 1.55; secondary 0.66 to 1.47)
Methods, limits and funding

Outcomes: CRP (a blood marker of inflammation)

Limitations: A survey, so it cannot show cause. Exposure was guessed from the type of protein drink, not measured. Subgroup finding only.

Funding and conflicts: Conflict statement: one author's spouse is employed by PepsiCo. No other conflicts stated for this work.

Read: abstract

McKim 2019
Clarifying the confusion between poligeenan, degraded carrageenan, and carrageenan: A review of the chemistry, nomenclature, and in vivo toxicology by the oral route.
Crit Rev Food Sci Nutr · PMID 29902080 · DOI
Narrative review chemistry toxicology
animal
Chemistry and animal oral toxicology of carrageenan, degraded carrageenan and poligeenan Carrageenan, degraded carrageenan, poligeenan
The authors argue that carrageenan cannot be turned into poligeenan inside the body and that older studies often used the word carrageenan for the degraded form, so concerns about the additive are unfounded.
No numbers in the abstract (Not applicable)
Methods, limits and funding

Outcomes: Chemistry, naming, toxicology

Limitations: Written by consultants; the carrageenan maker FMC Corporation is named in the follow-up addendum (Weiner 2017), and the funder of this paper is not stated in the abstract. Treat as industry-linked. A review, not a trial.

Funding and conflicts: Funding is not stated in this abstract. The related addendum carries an FMC Corporation copyright line, and the authors are consultants (IONTOX, TOXpertise, Celtic Colloids). Flagged as industry-linked.

Read: abstract

Tarlo 1995
Anaphylaxis to carrageenan: a pseudo-latex allergy.
J Allergy Clin Immunol · PMID 7751512 · DOI
Case report
1
One patient who had anaphylaxis during a barium enema
Carrageenan as a component of the barium enema solution
Carrageenan, a component of the barium enema solution, gave positive allergy skin test and IgE blood test results. The patient's stomach and bowel symptoms went away on a carrageenan-free diet. The authors called carrageenan a previously unreported cause of anaphylaxis during barium enema and suggested it could account for some symptoms from milk products or baby formula.
One patient (Not applicable)
Methods, limits and funding

Outcomes: Skin test and IgE blood test reactions to carrageenan

Limitations: A single 1995 case report. It shows allergy can happen but gives no rate. EFSA (2018) found no case reports of significant allergic reactions after eating foods that contain carrageenan.

Funding and conflicts: Funding is not stated in the abstract.

Read: abstract

Tobacman 2001
Review of harmful gastrointestinal effects of carrageenan in animal experiments.
Environ Health Perspect · PMID 11675262 · DOI
Narrative review animal studies
animal
Animal studies of carrageenan, degraded carrageenan and the gut Undegraded and degraded carrageenan
The author concluded that both undegraded and degraded carrageenan were linked to intestinal ulcers and tumours in animals, and that widespread use in the Western diet should be reconsidered. She suggested this could be from small-molecule contamination, breakdown by stomach acid, or gut bacteria.
No numbers in the abstract (Not applicable)
Methods, limits and funding

Outcomes: Gut ulcers and tumours in animals

Limitations: A 2001 narrative review of animal work, by one author; not a trial in people. Regulators and industry-funded reviews dispute that food-grade carrageenan breaks down into the harmful form in the body. Funding is not stated in the abstract.

Funding and conflicts: Funding is not stated in the abstract.

Read: abstract

Wagner 2024
Carrageenan and insulin resistance in humans: a randomised double-blind cross-over trial.
BMC Med · PMID 39593091 · DOI
Randomised crossover trial
20
20 healthy young men (average age 27.4 years, average BMI 24.5)
Carrageenan capsules versus placebo
Capsules 250 mg in the morning and 250 mg in the evening 2 weeks per treatment · vs Placebo (crossover)
Overall insulin sensitivity did not differ between carrageenan and placebo. There were differences by body weight: in overweight participants, carrageenan went with lower whole-body and liver insulin sensitivity, higher CRP and IL-6, a trend to more brain inflammation on MRI, and higher gut permeability. In cells from the participants' blood, carrageenan raised immune-cell activation in the lab.
Overall: no significant difference. BMI-by-treatment interaction p = 0.04 (insulin sensitivity index), p = 0.01 (fasting insulin resistance), p = 0.04 (liver insulin sensitivity index) (Not given in the abstract)
Methods, limits and funding

Outcomes: Insulin sensitivity (oral glucose test and clamp), CRP, IL-6, gut permeability, brain MRI, gut bacteria

Limitations: Only 20 men, 2 weeks, capsules. The overweight finding is a subgroup effect (an interaction) in a small trial, so it needs repeating. The authors' own conclusion is worded as 'may contribute'. Trial registration NCT02629705.

Funding and conflicts: Competing interests listed for some authors are lecture fees and advisory roles with drug companies (NovoNordisk, Eli Lilly, Sanofi and others), described as outside this work. No carrageenan industry funding is stated in the abstract.

Read: abstract

Weiner 2017
Addendum to Weiner, M.L. (2016) Parameters and Pitfalls to Consider in the Conduct of Food Additive Research, Carrageenan as a Case Study.
Food Chem Toxicol · PMID 28651808 · DOI
Commentary
n/a
Two recent publications that the authors say mislabel degraded carrageenan as carrageenan Not applicable
The authors say many papers use the name carrageenan for degraded carrageenan or poligeenan, which are not food additives and have very different properties, and call for rigorous peer review.
No numbers in the abstract (Not applicable)
Methods, limits and funding

Outcomes: Sample identity and study quality in carrageenan research

Limitations: A commentary, not a trial. Copyright line: FMC Corporation, a carrageenan maker.

Funding and conflicts: Industry-linked: copyright FMC Corporation (a carrageenan maker).

Read: abstract

s-efsa-2018
EFSA ANS Panel (2018). Re-evaluation of carrageenan (E 407) and processed Eucheuma seaweed (E 407a) as food additives. EFSA Journal 16(4):5238
· Source
Regulatory opinion
n/a

Methods, limits and funding

Read: full-text

s-fda-21cfr172-620
US eCFR, 21 CFR 172.620 Carrageenan
· Source
Regulation
n/a

Methods, limits and funding

Read: full-text

s-jecfa-carrageenan
WHO JECFA database: Carrageenan (INS 407)
· Source
Regulatory database
n/a

Methods, limits and funding

Read: full-text

What we do not know yet

  • No trial of carrageenan eaten as ordinary food was found for colitis, insulin or any other outcome.
  • Only three small human studies were read: a 12-person colitis trial, a 20-man insulin trial and a survey.
  • Whether food-grade carrageenan can break down into the harmful form in the body is argued by both sides and is not settled in people.
  • Liver safety, medicine interactions, pregnancy in people, heavy metals and iodine in the source seaweeds were not researched.
  • The 2016 US organic board vote was not rechecked and is not stated.

How new research is added

New studies are found by a saved PubMed search and placed in a review queue before the page changes.

Lab markers

What changed in blood or saliva tests during trials. A changed number is not the same as feeling or being healthier, and we give no "normal ranges".

Inflammatory 1

●

C-reactive protein (CRP)

Mixed: higher in overweight men in a trial; no overall link in a survey in trials

A blood marker that rises with inflammation.

Very low certainty
Results and what it means

Why it was measured

A simple check for body-wide inflammation.

Statistical vs. clinical meaning

Mixed and small; neither study shows cause.

Safety implication

None specific.

StudyResultPeopleProduct
7CRP and IL-6 higher with carrageenan in overweight participants20 young menCarrageenan 250 mg twice a day for 2 weeks
3Overall CRP ratio 1.07 (95% CI 0.74 to 1.55); poorer-health subgroup 1.91 (0.92 to 3.97)922 US adults using protein drinksCarrageenan-containing liquid protein drinks versus powder drinks (survey)

7 3

Other 3

●

Interleukin-6 and fecal calprotectin (gut inflammation markers)

Raised in the carrageenan group (IL-6); calprotectin trend in trials

IL-6 is an inflammation signal in the blood. Fecal calprotectin is a stool test that rises with gut inflammation.

Very low certainty
Results and what it means

Why it was measured

To see whether relapse in the colitis trial came with measurable inflammation.

Statistical vs. clinical meaning

A small signal in a tiny trial; the calprotectin change did not reach the usual p < 0.05 cut-off.

Safety implication

Relevant to people with ulcerative colitis; see Safety.

StudyResultPeopleProduct
1IL-6 rose in the carrageenan group (p = 0.02); fecal calprotectin rose with p = 0.06 (not significant); neither rose in the placebo group12 adults with ulcerative colitis in remissionCarrageenan capsules versus placebo, up to 1 year

1

●

Insulin sensitivity

No overall change; lower in overweight participants in trials

How well the body responds to insulin to bring blood sugar down. Lower sensitivity (insulin resistance) is linked to type 2 diabetes.

Very low certainty
Results and what it means

Why it was measured

Animal studies suggested carrageenan could reduce it.

Statistical vs. clinical meaning

A subgroup signal in a small trial.

Safety implication

Relevant to people with prediabetes or diabetes; see Safety.

StudyResultPeopleProduct
7No significant overall difference; lower whole-body and liver insulin sensitivity in overweight participants (interaction p = 0.01 to 0.04)20 healthy young men (BMI average 24.5)Carrageenan 250 mg twice a day for 2 weeks versus placebo

7

●

Gut permeability (leaky gut markers)

Higher in the carrageenan period in trials

How easily substances pass through the gut lining, measured by a lactulose-mannitol test and blood zonulin.

Very low certainty
Results and what it means

Why it was measured

To test the idea that carrageenan inflames or loosens the gut lining.

Statistical vs. clinical meaning

A single small trial; no numbers in the abstract.

Safety implication

Unknown.

StudyResultPeopleProduct
7Carrageenan was associated with increased intestinal permeability (the abstract gives no numbers)20 healthy young menCarrageenan 250 mg twice a day for 2 weeks versus placebo

7

Safety

What studies and official sources say about side effects, medicines and who should check first. Each point shows what kind of evidence it comes from.

Main points to know 4
  • Regulators accept food-grade carrageenan at current use, but the question is not closed. EFSA (2018) found no concern about cancer or genetic damage, but kept the acceptable daily intake as temporary because of gaps in the data. In its worst-case scenario for people who always buy the same brands, high intakes were up to about 10 times that temporary limit. EFSA said this may be overestimated but may be a safety concern. JECFA (FAO/WHO) lists the limit as 'not specified'. The US FDA allows it as a thickener, stabilizer or emulsifier. Authoritative guidance 9 11 10
  • Do not mix up food carrageenan with poligeenan (degraded carrageenan). Poligeenan is a much smaller molecule made on purpose with strong acid and heat. EFSA says it has never been authorised as a food additive and is not used in food. Much of the animal work on gut damage and tumours used this form. IARC (1983, as quoted by EFSA) put carrageenan in group 3 (not classifiable) and degraded carrageenan in group 2B (possibly carcinogenic to humans) on rat evidence. Critics say the food additive can break down into the harmful form in the gut; reviewers linked to a carrageenan maker say it cannot. This is unresolved in people. Authoritative guidance 9 6 4 8 2
  • People with ulcerative colitis or other inflammatory bowel disease: ask your gut doctor. In one very small trial (12 finishers), 3 people with ulcerative colitis given carrageenan capsules relapsed and none given placebo did. EFSA said this needs further investigation and that results suggesting carrageenan might make inflammatory bowel disease worse in people need clarification. It is a signal, not proof. Randomised trial very small 1 9
  • Babies: EU and WHO advice differ. JECFA (2014) found carrageenan in infant formula up to 1000 mg per litre not of concern, for infants usually under medical supervision. EFSA (2018) did not adopt that view and repeated the earlier EU committee advice that it remains inadvisable in infant formula fed from birth, including formulas for special medical purposes. The EU limit for adults does not apply to babies under 12 weeks. Ask a paediatrician about formula. Authoritative guidance 9 11
Side effects 2
EffectHow oftenSeverity and recoveryEvidence
Allergic reaction (rare). One case of anaphylaxis during a barium enema was linked to carrageenan by skin and blood tests.
A rate is not known. Do not read this as a common reaction.
One case report from 1995. EFSA found no case reports of significant allergic or anaphylactic reactions after eating foods that contain carrageenan.can be severe (anaphylaxis) in the one case reported
Not described beyond that symptoms stopped on a carrageenan-free diet in that case.
Case report 5 9
Higher gut permeability and, in overweight men, lower insulin sensitivity and higher CRP and IL-6, over 2 weeks of carrageenan capsules
Capsules, not food. A small trial that needs repeating.
20 healthy young men in one crossover trial; the overall insulin result was not significant and the overweight finding is a subgroup effect.No symptoms reported in the abstract; lab changes only
Not reported.
Randomised trial very small 7
Liver

No liver injury from carrageenan was found in the sources read. A liver-safety source (such as LiverTox) was not searched for carrageenan.

How often. No frequency was found.

Monitoring. No agency monitoring advice was found.

This is a safety connection. It is not evidence that Carrageenan supports liver health.

Medicines and supplements 1
WithWhy it mattersImportanceEvidenceWhat to do
Prescription and over-the-counter medicines
prescription
No source read describes a medicine interaction with carrageenan. Diabetes medicines, colitis medicines and others were not specifically searched.None found Not enough evidence A pharmacist can check your own medicines, especially if you take medicine for diabetes or ulcerative colitis.
Who should check first 6
SituationAdviceEvidence
Ulcerative colitis, Crohn's disease or other bowel inflammationAsk your gut doctor whether to limit carrageenan. The evidence is one very small trial and animal work.Randomised trial very small 1 9
Babies, especially infant formula fed from birthEFSA says it remains inadvisable in infant formula fed from birth; JECFA reached a different view for infants under medical supervision. Ask a paediatrician.Authoritative guidance 9 11
Known allergy to carrageenanAvoid it and read labels (it may be listed as carrageenan or E407). Ask an allergist. For trouble breathing or swelling of the face or throat, call 911 or your local emergency number.Case report 5
Prediabetes, type 2 diabetes or overweightAsk your doctor. One small trial saw lower insulin sensitivity in overweight men on carrageenan capsules; it needs repeating.Randomised trial very small 7
Pregnancy and breastfeedingNo human study or official pregnancy statement for carrageenan was read. EFSA reports animal studies where the highest dose tested caused no developmental harm in studies of sodium and calcium carrageenan. Ask your midwife or doctor about your own diet.Animal and regulatory 9
Young children and single-bite jelly sweetsEFSA (2004 opinion, quoted in 2018) said gel-forming additives, including carrageenan, in single-bite jelly mini-cups carry a choking risk. Their use in jelly mini-cups is not authorised in the EU. Keep gel sweets and jelly cups away from young children.Authoritative guidance 9
Overdose, product quality and regulators

Summary. Food-grade carrageenan was well tolerated in animal studies reviewed by EFSA. The safety questions are the broken-down form, how much people actually eat, and gut inflammation in people.

Animal. EFSA: not absorbed intact. No harm at the highest doses tested in rats (3,400 to 3,900 mg per kg body weight per day for a subchronic study; up to 7,500 mg per kg per day in chronic studies). Degraded carrageenan caused colon lesions and ulceration in monkeys, and colitis then tumours in rats, per EFSA.

Human doses studied. Capsules of 250 mg twice a day for 2 weeks (insulin trial) and a lower amount than average dietary intake (colitis trial). No amount advice is given here.

High dose or long term signals. The EU acceptable daily intake is 75 mg per kg body weight per day and is called temporary. EFSA's refined worst-case estimate for people loyal to certain brands was up to about 10 times that at the 95th percentile.

Overdose response. Not found.

Genotoxicity. EFSA: carrageenan and processed Eucheuma seaweed did not raise a concern for genetic damage.

Quality is mainly about how small the carrageenan molecules are and what is left over from processing. Heavy metals and iodine in the source seaweed were not researched for this page.

Small-molecule fraction. EU rules limit the share of low-weight carrageenan (below 50 kDa), because it looks like the degraded form. One interested party told EFSA that material on the market does not always meet that limit. EFSA asked for a validated test method. 9

Bleach by-product in processed Eucheuma seaweed. EFSA notes that processed Eucheuma seaweed (E 407a) is sometimes bleached with calcium hypochlorite, which can raise a by-product called semicarbazide, and that industry has been trying other bleaching agents. EU rules also cap formaldehyde at 50 mg per kg of additive. 9

BodyActionDate
US FDA (21 CFR 172.620) (United States)Carrageenan may be safely used in food as an emulsifier, stabilizer or thickener in the amount necessary. It is the refined hydrocolloid from named red seaweeds, a sulfated polysaccharide with 20 to 40 percent sulfate. source2026-10-01
EFSA (European Union)2018 re-evaluation of carrageenan (E 407) and processed Eucheuma seaweed (E 407a): no concern for cancer or genetic damage; group acceptable daily intake of 75 mg per kg body weight per day made temporary; data to be improved within 5 years; inadvisable in infant formula fed from birth. source2018-04
WHO and FAO JECFA (International)2014 (79th meeting): acceptable daily intake not specified; carrageenan in infant formula up to 1000 mg per litre not of concern. 2007 listing: inadvisable in infant formulas. source2014
IARC (as quoted by EFSA) (International)1983: carrageenan group 3 (not classifiable); degraded carrageenan group 2B based on rat evidence, no human data. source1983
When to get medical help
  • Trouble breathing, wheezing, swelling of the lips, face, tongue or throat, widespread hives or collapse after eating: possible anaphylaxis. Use epinephrine if prescribed, then call 911 or your local emergency number.
  • Ulcerative colitis or Crohn's disease getting worse: blood in the stool, new severe diarrhoea or belly pain. Contact your gut doctor.
  • A child choking on a jelly sweet or jelly cup: call 911 or your local emergency number.

Stop using the product and contact a clinician or emergency service. In the US, Poison Control is 1-800-222-1222.

General information only, not medical advice. Ask a clinician or pharmacist before use, especially with medicines, in pregnancy or with a health condition. See the Natural Remedy Safety guide.

Frequently asked questions

What is carrageenan?

A thickener and gelling agent taken from red seaweeds, labelled carrageenan or E407. It holds together dairy and plant drinks, desserts and processed meats.

10 9

Is carrageenan safe?

Regulators accept food-grade carrageenan at current use: FDA allows it, JECFA lists the limit as not specified, and EFSA found no concern for cancer or genetic damage. EFSA still made the EU limit temporary because of data gaps, so the question is open.

10 11 9

Is carrageenan the same as poligeenan?

No. Poligeenan is a much smaller molecule made with acid and heat and is not allowed in food. Much of the animal gut-damage work used it. Whether the food additive can break down into it in the body is argued by both sides.

9 6 4

Does carrageenan cause cancer?

No human study shows it. EFSA found no concern for cancer from food-grade carrageenan; IARC (1983, as quoted by EFSA) put it in group 3, not classifiable, and degraded carrageenan in group 2B on rat evidence. A 2001 review argued for caution; a 2002 review found no credible evidence of colon tumour promotion.

9 6 2

Does carrageenan make ulcerative colitis worse?

Possibly, but proof is thin. In one trial, 3 of those given carrageenan capsules relapsed and none given placebo did, but only 12 people finished. EFSA said this needs further investigation. Ask your gut doctor.

1 9

Does carrageenan affect blood sugar or insulin?

A 2-week trial in 20 healthy young men found no overall change in insulin sensitivity. In overweight men it was lower and CRP and IL-6 were higher. It is one small trial and needs repeating.

7

Is carrageenan okay in infant formula?

The sources differ. JECFA (2014) found up to 1000 mg per litre not of concern for infants under medical supervision. EFSA (2018) repeated that it remains inadvisable in infant formula fed from birth. Ask a paediatrician.

11 9

Is carrageenan allergenic?

It seems rare. One 1995 case report linked anaphylaxis during a barium enema to carrageenan, and EFSA found no case reports from eating it in foods. If you have swelling of the face or trouble breathing, call 911 or your local emergency number.

5 9

Is carrageenan the same as sea moss?

No. Carrageenan is a refined extract. Whole sea moss is a seaweed that is a source of carrageenan, and no study shows they act the same.

10 9

Is carrageenan safe in pregnancy?

No human study or official pregnancy statement for carrageenan was found. EFSA reports animal studies of sodium and calcium carrageenan with no developmental harm at the highest dose tested. Ask your midwife or doctor.

9

What does it mean that the EU limit is temporary?

EFSA kept the group limit of 75 mg per kg body weight per day but called it temporary because of gaps in the chemistry, intake and biology data, and asked for better data within 5 years of its 2018 opinion. It is a request for more evidence, not a finding of harm.

9

Can I avoid carrageenan?

It is listed as carrageenan or E407 (E407a for processed Eucheuma seaweed) on labels. Many products have versions without it. Whether avoiding it helps your health is not shown by trials.

10 9

Explore by health goal

Gut HealthDigestive SupportBlood Sugar BalanceInflammation BalancePreventive Wellness

Editorial transparency
Written by
AlternativeMed editorial team. Research compiled with AI assistance, then checked against the sources listed.
Medical review
None. This page has not been reviewed by a physician or pharmacist.
First published
2026-10-26
Last substantive update
2026-10-26
How we research
We started from our existing carrageenan summary, read the EFSA 2018 opinion, the JECFA database page and the US regulation text, and re-read PubMed abstracts for the trials, reviews and a case report. Only abstracts were read for studies. Items we could not verify are flagged in the research gaps.
How we rate evidence
See "How we rate evidence" in the Evidence tab.
Independence
No product is promoted on this page. No affiliate links are shown. Two cited reviews are by consultants linked to a carrageenan maker and the 2001 review and the colitis trial include an author who has argued against carrageenan; this is stated where they are used.
Sources 11

Each source was opened and checked. Where we read only the abstract, it says so. The small numbers in the text point here.

  1. Bhattacharyya S, Shumard T, Xie H, Dodda A, et al.. A randomized trial of the effects of the no-carrageenan diet on ulcerative colitis disease activity.. Nutr Healthy Aging. 2017. PMID 28447072. DOI 10.3233/NHA-170023. (abstract)
  2. Cohen SM, Ito N. A critical review of the toxicological effects of carrageenan and processed eucheuma seaweed on the gastrointestinal tract.. Crit Rev Toxicol. 2002. PMID 12389870. DOI 10.1080/20024091064282. (abstract)
  3. Lam CS, O'Connell K, Monroy-Iglesias MJ, Du M, et al.. Evaluation of the Association Between Carrageenan and Systemic Inflammation: Results From the National Health and Nutrition Examination Survey.. Mol Nutr Food Res. 2026. PMID 42117307. DOI 10.1002/mnfr.70484. (abstract)
  4. McKim JM, Willoughby JA Sr, Blakemore WR, Weiner ML. Clarifying the confusion between poligeenan, degraded carrageenan, and carrageenan: A review of the chemistry, nomenclature, and in vivo toxicology by the oral route.. Crit Rev Food Sci Nutr. 2019. PMID 29902080. DOI 10.1080/10408398.2018.1481822. (abstract)
  5. Tarlo SM, Dolovich J, Listgarten C. Anaphylaxis to carrageenan: a pseudo-latex allergy.. J Allergy Clin Immunol. 1995. PMID 7751512. DOI 10.1016/s0091-6749(95)70091-9. (abstract)
  6. Tobacman JK. Review of harmful gastrointestinal effects of carrageenan in animal experiments.. Environ Health Perspect. 2001. PMID 11675262. DOI 10.1289/ehp.01109983. (abstract)
  7. Wagner R, Buettner J, Heni M, Fritsche L, et al.. Carrageenan and insulin resistance in humans: a randomised double-blind cross-over trial.. BMC Med. 2024. PMID 39593091. DOI 10.1186/s12916-024-03771-8. (abstract)
  8. Weiner ML, McKim JM, Blakemore WR. Addendum to Weiner, M.L. (2016) Parameters and Pitfalls to Consider in the Conduct of Food Additive Research, Carrageenan as a Case Study.. Food Chem Toxicol. 2017. PMID 28651808. DOI 10.1016/j.fct.2017.06.022. (abstract)
  9. . EFSA ANS Panel (2018). Re-evaluation of carrageenan (E 407) and processed Eucheuma seaweed (E 407a) as food additives. EFSA Journal 16(4):5238. . . (full-text)
  10. . US eCFR, 21 CFR 172.620 Carrageenan. . . (full-text)
  11. . WHO JECFA database: Carrageenan (INS 407). . . (full-text)

Where to buy

Check the label first. Whatever you buy, look for these:

  • The iodine amount: seaweed can be very high in iodine, which matters for thyroid conditions
  • Heavy metal testing information from the maker
  • Origin and harvest area
  • Organic or tested labeling

Talk to a pharmacist or doctor before you start any supplement, especially if you take medicines. See the Safety tab for interactions.

Browse Carrageenan on Amazon
Amazon · Several brands to compare
Shop Carrageenan on Amazon

Support our free guides: as an Amazon Associate we earn from qualifying purchases. Full disclosure.

Education, not medical advice. This page is for general information. It does not diagnose or treat any condition and is not a substitute for care from a qualified health professional. Natural does not automatically mean safe. Ask a clinician or pharmacist before changing your care, especially if you take medication, are pregnant or breastfeeding, or have a health condition.